Antibody Developability Assessment: Find Risk Before It Finds You
Mosaic delivers early developability screening, biophysical characterization, and binding analytics to help biopharma and biotech teams de-risk candidates before committing to costly downstream studies.
216+
Discovery programs completed to date.
80%
Of scientific staff hold advanced degrees (PhD/MS).
504+
Peer-reviewed publications and patents authored by Mosaic scientists.
50+
Experienced scientists and program leaders.
100%
Research conducted in the USA.
Comprehensive Biophysical Characterization & Analytics
Label-free, real-time characterization of protein-protein interactions using purified or non-purified samples:
SPR and BLI kinetics (KD, ka, kd)
Epitope binning and competition studies
Solution-based orthogonal confirmations
Species cross-reactivity profiling
Affinity ranking and concentration determination
Developability & Analytics
Rigorous biophysical and biochemical characterization to assess quality, stability, and developability early:
HPLC-based purity and aggregation profiling
Interferometry and plate-based stability assessment
Forced degradation studies
Antibody and protein developability assessments
In-use stability studies for formulation optimization
Analytical Toolkit SPR & BLI · HPLC (SEC, IEX, RP) · Interferometry · Plate Readers · ELISA Platforms · Mass Spectrometry
Decision-Ready Data at Every Stage
Mosaic’s protein sciences and analytics teams work in close integration to ensure every assay is technically sound, reproducible, and decision-relevant, so your team can move forward with confidence.
Protein expression and production with rigorous QC
Assay development and fit-for-purpose qualification
Comprehensive biophysical and analytical characterization
Analysis, interpretation, and reporting to support discovery decisions
Experts From the World’s Top Organizations
Eric Furfine, PhD
Chief Scientific Officer
Led IPO-financed Phase 3 programs at Eleven Biotherapeutics. Built the Adnectin platform (acquired by BMS). Former VP at Regeneron contributing to Eylea development.
Tracy Mullen
Chief Strategy Officer
Former SVP Biopharma at Twist Bioscience (post-Abveris acquisition). Former CEO of Abveris. Antibody discovery leadership experience at Biogen and Adimab platform implementation.
Alexei Kazantsev, PhD
Sr. Director Protein Design and Engineering
Structural and chemical biology expert. Leads protein engineering and PK optimization at Mosaic. Prior research in RNA and protein structural biology using X-ray crystallography and SAXS.
Scott Glaser PhD
SVP, Biologics Discovery
30+ years in biologic drug discovery. Former Director of Antibody Therapeutics at Novartis (GNF) and senior leadership at Pfizer and Biogen. Contributor to 50+ discovery programs and co-inventor on 23 US patents.
Ready to De-Risk Your Lead Candidates?
Tell us about your program and what you’re trying to characterize. Our scientific team responds within one business day.
Start a conversation with our scientific team about your discovery program today